Antithrombotic effect of Z4A5 on coronary thrombosis in a canine model of acute unstable angina

British Journal of Pharmacology

Volumn 169, Issue 4, 2013, Pages 848-859

  Jing, Bo Bin ^a,b   Li, Ying Xue ^a,c   Zhang, Hui ^a,c   Ren, Shu Ting ^a,c   Wang, Mei ^a   Li, Yi Ping ^a,c   Shen, Xin Liang ^d   Wang, Yi Li ^a   Zang, Wei Jin ^a   Wang, Bing ^a,c  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b National Vaccine and Serum Institute   (China)

^c Therapeutic Vaccines Engineering Center   (China)

^d China National Biotec Group   (China)

Author keywords

cyclic flow reduction; glycoprotein IIb IIIa receptor antagonist; platelet aggregation; unstable angina; Z4A5

Indexed keywords

ADENOSINE DIPHOSPHATE; FIBRINOGEN RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG; Z 4A 5;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPLATELET ACTIVITY; ANTITHROMBOTIC EFFECT; ARTICLE; BLEEDING TIME; BLOOD CLOTTING PARAMETERS; CONCENTRATION RESPONSE; CONTINUOUS INFUSION; CONTROLLED STUDY; CORONARY ARTERY CIRCUMFLEX BRANCH; CORONARY ARTERY THROMBOSIS; CYCLIC FLOW REDUCTION; DOG; DOSE RESPONSE; DRUG ACTIVITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG STRUCTURE; FEMALE; HEART MUSCLE ISCHEMIA; HEMATOLOGICAL PARAMETERS; HEMODYNAMIC PARAMETERS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE RICH PLASMA; TONGUE; UNSTABLE ANGINA PECTORIS; VASOCONSTRICTION;

ANGINA, UNSTABLE; ANIMALS; ANTICOAGULANTS; BLOOD COAGULATION; CORONARY THROMBOSIS; DISEASE MODELS, ANIMAL; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUGS, INVESTIGATIONAL; FEMALE; FEMORAL ARTERY; FIBRINOLYTIC AGENTS; HEMODYNAMICS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; OLIGOPEPTIDES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RABBITS; THROMBOSIS;

EID: 84878342140     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12026     Document Type: Article

References (32)

1. Alexander KP, Chen AY, Newby K, Schwartz JB, Redberg RF, Hochman JS, et al. (2006). Sex differences in major bleeding with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the ACC/AHA Guidelines) initiative. Circulation 114: 1380-1387.
2. Anderson HV, Kirkeeide RL, Krishnaswami A, Weigelt LA, Revana M, Weisman HF, et al. (1994). Cyclic flow variations after coronary angioplasty in humans: clinical and angiographic characteristics and elimination with 7E3 monoclonal antiplatelet antibody. J Am Coll Cardiol 23: 1031-1037.
3. Barrett NE, Holbrook L, Jones S, Kaiser WJ, Moraes LA, Rana R, et al. (2008). Future innovations in anti-platelet therapies. Br J Pharmacol 154: 918-939.
4. Bengmark S, Elmer O, Goransson G, Zoucas E, (1981). In vitro effect of ethanol on ADP and collagen-induced platelet aggregation. Thromb Haemost 46: 673-675.
5. Bennett JS, (2001). Novel platelet inhibitors. Annu Rev Med 52: 161-184.
6. Bertha BG, Folts JD, (1984). Inhibition of epinephrine-exacerbated coronary thrombus formation by prostacyclin in the dog. J Lab Clin Med 103: 204-214.
7. Braunwald E, (1998). Unstable angina: an etiologic approach to management. Circulation 98: 2219-2222.
8. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, et al. (2002). ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients with Unstable Angina). J Am Coll Cardiol 40: 1366-1374.
9. Chew DP, Bhatt DL, Sapp S, Topol EJ, (2001). Increased mortality with oral platelet glycoprotein IIb/IIIa antagonsists. A meta-analysis of phase III multicenter randomized trials. Circulation 103: 201-206.
10. Damiano BP, Mitchell JA, Giardino E, Corcoran T, Haertlein BJ, de, Garavilla L, et al. (2001). Antiplatelet and antithrombotic activity of RWJ-53308, a novel orally active glycoprotein IIb/IIIa antagonist. Thromb Res 104: 113-126.
11. Danchin N, Aïssaoui N, (2010). Pharmacologic therapy for non ST-segment elevation acute coronary syndromes: focus on antithrombotic therapy. Cardiovasc Drugs Ther 24: 325-330.
12. Eichhorn EJ, Grayburn PA, Willard JE, Anderson HV, Bedotto JB, Carry M, et al. (1991). Spontaneous alterations in coronary blood flow velocity before and after coronary angioplasty in patients with severe angina. J Am Coll Cardiol 17: 43-52.
13. Hamm CW, Heeschen C, Goldmann B, Vahanian A, Adgey J, Miguel CM, et al. (1999). For the CAPTURE Study Investigators. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. N Engl J Med 340: 1623-1629.
14. Harding SA, Boon NA, Flapan AD, (2002). Antiplatelet treatment in unstable angina: aspirin, clopidogrel, glycoprotein IIb/IIIa antagonist, or all three? Heart 88: 11-14.
15. Jackson SP, Nesbitt WS, Kulkarni S, (2003). Signaling events underlying thrombus formation. J Thromb Haemost 1: 1602-1612.
16. Jennings LK, (2009). Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis. Thromb Haemost 102: 248-257.
17. Jing BB, Li YX, Zhang H, Ren ST, Wang M, Li YP, et al. (2011). Antithrombotic activity of Z4A5, a new platelet glycoprotein IIb/IIIa receptor antagonist evaluated in a rabbit arteriovenous shunt thrombosis model. Thromb Res 128: 463-469.
18. Kao HL, Lin LC, Wu CC, Liau CS, Lee YT, (2002). Suppression of cyclic coronary flow variation and reduction of restenosis with abciximab for morphologically high-risk lesions undergoing percutaneous coronary. J Cardiovasc Pharmacol 39: 901-908.
19. Kong DF, Califf RM, Miller DP, Moliterno DJ, White HD, Harrington RA, et al. (1998). Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation 98: 2829-2835.
20. Kurz KD, Main BW, Sandusky GE, (1990). Rat model of arterial thrombosis induced by ferric chloride. Thromb Res 60: 269-280.
21. Li YX, Sun Q, Zhang H, Ren ST, Liao YR, Wang Y, et al. (2012). A novel anti-platelet peptide (Z4A5) potential for glycoprotein IIb/IIIa inhibits platelet aggregation. Thromb Res 129: 217-222.
22. Lynch JJ, Cook JJ, Sitko GR, Holahan MA, Ramjit DR, Mellott MJ, et al. (1995). Nonpeptide glycoprotein IIb/IIIa inhibitors. 5. Antithrombotic effects of MK-0383. J Pharmacol Exp Ther 272: 20-32.
23. Makkar RR, Litvack F, Eigler NL, Nakamura M, Ivey PA, Forrester JS, et al. (1997). Effects of GP IIb/IIIa receptor monoclonal antibody (7E3), heparin, and aspirin in an ex vivo canine arteriovenous shunt model of stent thrombosis. Circulation 95: 1015-1021.
24. McGrath J, Drummond G, Kilkenny C, Wainwright C, (2010). Guidelines for reportingexperiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
25. Phillips DR, Charo IF, Scarborough RM, (1991). GPIIb-IIIa: the responsive integrin. Cell 65: 359-362.
26. Plow EF, Pierschbacher MD, Ruoslahti E, Marguerie GA, Ginsberg MH, (1985). The effect of Arg-Gly-Asp-containing peptides on fibrinogen and von Willebrand factor binding to platelets. Proc Natl Acad Sci U S A 82: 8057-8061.
27. Priomos G, (2001). Platelet aggregation inhibition with glycoprotein IIb-IIIa inhibitors. J Thromb Thrombolysis 11: 99-110.
28. Speich HE, Earhart AD, Hill SN, Cholera S, Kueter TJ, Smith JN, et al. (2009). Variability of platelet aggregate dispersal with glycoprotein IIb-IIIa antagonists eptifibatide and abciximab. J Thromb Haemost 7: 983-991.
29. Tricoci PT, Peterson ED, (2006). The evolving role of glycoprotein IIb/IIIa inhibitor therapy in contemporary care of acute coronary syndrome patients. J Interv Cardiol 19: 449-455.
30. Wang YS, Wu BT, Shu XH, (2012). Meta-analysis of randomized controlled trials comparing intracoronary and intravenous administration of glycoprotein IIb/IIIa inhibitors in patients with ST-elevation myocardial infarction. Am J Cardiol 109: 1124-1130.
31. Wu D, Vanhoorelbeke K, Cauwenberghs N, Meiring M, Depraetere H, Kotze HF, et al. (2002). Inhibition of the von Willebrand (VWF)-collagen interaction by an antihuman VWF monoclonal antibody results in abolition of in vivo arterial platelet thrombus formation in baboons. Blood 99: 3623-3628.
32. Zhou XB, Qin H, Li J, Wang B, Wang CB, Liu YM, et al. (2011). Platelet-targeted microbubbles inhibit re-occlusion after thrombolysis with transcutaneous ultrasound and microbubbles. Ultrasonics 51: 270-274.